Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 32, Issue 36, p.4066-72 (2014)


Aged, Antigens, Neoplasm, Biopsy, Early Detection of Cancer, Humans, Male, Middle Aged, Prospective Studies, prostate, Prostate-Specific Antigen, Prostatic Neoplasms, Risk Assessment


Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA.